178 related articles for article (PubMed ID: 33594044)
1. Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.
Liu M; Wang D; Luo Y; Hu L; Bi Y; Ji J; Huang H; Wang G; Zhu L; Ma J; Kim E; Luo CK; Abbruzzese JL; Li X; Yang VW; Li Z; Lu W
Cell Death Dis; 2021 Feb; 12(2):189. PubMed ID: 33594044
[TBL] [Abstract][Full Text] [Related]
2. Selective killing of K-ras-transformed pancreatic cancer cells by targeting NAD(P)H oxidase.
Wang P; Sun YC; Lu WH; Huang P; Hu Y
Chin J Cancer; 2015 Apr; 34(4):166-76. PubMed ID: 25963558
[TBL] [Abstract][Full Text] [Related]
3. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
[TBL] [Abstract][Full Text] [Related]
5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
6. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
9. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T
Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
12. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
13. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts.
Doroshow JH; Gaur S; Markel S; Lu J; van Balgooy J; Synold TW; Xi B; Wu X; Juhasz A
Free Radic Biol Med; 2013 Apr; 57():162-75. PubMed ID: 23314043
[TBL] [Abstract][Full Text] [Related]
14. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
15. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
[TBL] [Abstract][Full Text] [Related]
16. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Blasco MT; Navas C; Martín-Serrano G; Graña-Castro O; Lechuga CG; Martín-Díaz L; Djurec M; Li J; Morales-Cacho L; Esteban-Burgos L; Perales-Patón J; Bousquet-Mur E; Castellano E; Jacob HKC; Cabras L; Musteanu M; Drosten M; Ortega S; Mulero F; Sainz B; Dusetti N; Iovanna J; Sánchez-Bueno F; Hidalgo M; Khiabanian H; Rabadán R; Al-Shahrour F; Guerra C; Barbacid M
Cancer Cell; 2019 Apr; 35(4):573-587.e6. PubMed ID: 30975481
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.
Li X; Li M; Ruan H; Qiu W; Xu X; Zhang L; Yu J
Oncotarget; 2017 Feb; 8(6):9280-9292. PubMed ID: 28030835
[TBL] [Abstract][Full Text] [Related]
18. The NADPH oxidase inhibitor diphenyleneiodonium activates the human TRPA1 nociceptor.
Suzuki H; Hatano N; Muraki Y; Itoh Y; Kimura S; Hayashi H; Onozaki K; Ohi Y; Haji A; Muraki K
Am J Physiol Cell Physiol; 2014 Aug; 307(4):C384-94. PubMed ID: 24944203
[TBL] [Abstract][Full Text] [Related]
19. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
20. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
Urrutia G; Salmonson A; Toro-Zapata J; de Assuncao TM; Mathison A; Dusetti N; Iovanna J; Urrutia R; Lomberk G
Mol Cancer Res; 2020 Mar; 18(3):448-462. PubMed ID: 31822519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
